# Comparative PK PD Study in PAH Patients (Fox vs. I-Neb)

> **NCT02032836** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 27 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** lloprost(Ventavis,BAYQ6252, 20 µg/mL)
- **DRUG:** lloprost(Ventavis,BAYQ6252, 10 µg/mL)

## Key facts

- **NCT ID:** NCT02032836
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-10
- **Primary completion:** 2015-01-07
- **Final completion:** 2017-09-29
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2018-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02032836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02032836, "Comparative PK PD Study in PAH Patients (Fox vs. I-Neb)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02032836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*